NEW YORK (TheStreet) -- Intercept Pharmaceuticals (ICPT) shares are up 45.88% to $346 in pre-market trading on Tuesday after releasing positive data on its fatty liver drug treatment, obeticholic acid (OCA).
The new data shows OCA reduced the signs and symptoms of non-alcoholic steatohepatitis (NASH) compared to placebo. NASH is a disease of the liver that affects 2% to 5% of Americans and has no current treatment.
Intercept plans to start a phase III study of OCA in NASH next year.
Highlights from the analysis by TheStreet Ratings Team follows:
- You can view the full analysis from the report here: ICPT Ratings Report
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE